Agilent Technologies (A) and Danaher (DHR) screen as potential buyers of Qiagen (QGEN) after a report that the European ...
QIAGEN N.V. QGEN, together with Myriad Genetics MYGN, will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. The endeavor expands upon the ...
Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved ...
Venlo, the Netherlands, March 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (QGEN) (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the release of the QIAstat-Dx Analyzer 2.0, including the Software ...
Germantown, Maryland, and Venlo, the Netherlands, June 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Gastrointestinal ...
Molecular diagnostics company Qiagen launched the first syndromic test that differentiates between monkeypox and five other viruses with similar symptoms. The QIAstat-Dx Viral Vesicular Panel is ...
Here are three things to know. The Quantiferon-TB Gold Plus test is designed to detect latent tuberculosis in patients. The blood test offers a broad look into an individual’s immune response to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results